董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Elisha W. Finney | 女 | Independent Director | 64 | 29.63万美元 | 0.19 | 2026-05-07 |
| Domitille Doat Le Bigot | 女 | Independent Director | 53 | 29.01万美元 | 0.14 | 2026-05-07 |
| Wolfgang Wienand | 男 | Independent Director | 54 | 28.13万美元 | 0.05 | 2026-05-07 |
| Pablo Perversi | 男 | Independent Director | 55 | 19.50万美元 | 0.0063 | 2026-05-07 |
| Thomas P. Salice | 男 | Independent Director | 66 | 35.31万美元 | 7.72 | 2026-05-07 |
| Michael J. Tokich | 男 | Independent Director | 57 | 未披露 | 0.0050 | 2026-05-07 |
| Brian Shepherd | 男 | Independent Director | 59 | 27.88万美元 | 0.02 | 2026-05-07 |
| Roland Diggelmann | 男 | Chairman of the Board and Independent Director | 58 | 75.30万美元 | 0.14 | 2026-05-07 |
| Ingrid Zhang | 女 | Independent Director | 53 | 28.13万美元 | 0.07 | 2026-05-07 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Patrick Kaltenbach | 男 | Chief Executive Officer and President | 62 | 674.12万美元 | 2.33 | 2026-05-07 |
| Shawn P. Vadala | 男 | Chief Financial Officer | 57 | 238.49万美元 | 1.85 | 2026-05-07 |
| Gerhard Keller | 男 | Head of Process Analytics | 58 | 134.04万美元 | 未持股 | 2026-05-07 |
| Richard Wong | 男 | Head of Asia/Pacific | 61 | 120.93万美元 | 0.43 | 2026-05-07 |
| Susan Graham Bryce | 女 | Chief Human Resources Officer | 50 | 234.93万美元 | 0.03 | 2026-05-07 |
| Oliver Wittorf | 男 | Head of Product Inspection, Retail, and Global Supply Chain | 50 | 未披露 | 未持股 | 2026-05-07 |
董事简历
中英对照 | 中文 | 英文- Elisha W. Finney
-
Elisha W. Finney，自2017年11月起担任董事。她担任审计委员会主席。她拥有乔治亚大学风险管理和保险工商管理学士学位，金门大学工商管理硕士学位。Finney是NanoString Technologies，Inc.的董事和审计委员会主席，以及ICU Medical, Inc.和Viatris Inc.的董事，她是这两家公司的审计委员会成员。她此前曾担任Cutera，Inc.的董事至2019年6月，Irobot Corporation至2021年11月。Finney女士自1999年至2017年6月退休期间一直担任Varian医疗 Inc.的首席财务官。她于1988年加入Varian，在被任命为首席财务官之前曾担任过多种财务职务。
Elisha W. Finney has been a director since January 2016, and serves as Chair of the Nominating and Governance Committee and is a member of the Audit Committee. Ms. Finney, now retired, was named Vice President, Finance and CFO of Varian Medical Systems in April 1999. In January 2005, she was promoted to Senior Vice President and given additional management responsibility for the Corporate Information Systems group. She was named Executive Vice President in February 2012. Varian Medical Systems is a leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy. Ms. Finney managed a worldwide staff of 400. Her management responsibilities included corporate accounting; corporate communications and investor relations; internal financial and compliance audit; risk management; tax and treasury, and corporate information systems. Ms. Finney joined Varian as risk manager in 1988 and has assumed a wide variety of finance functions over her last 29 years with the company. Prior to joining Varian, Ms. Finney was with the Fox Group in Foster City, CA, and Beatrice Foods, a major food processing company, in Chicago, IL. Ms. Finney has served on the boards of: Mettler Toledo, a multinational manufacturer of scales and analytical instruments, since November 2017; and Viatris, a global pharmaceutical and healthcare corporation, since December 2022. Ms. Finney previoly served on the boards of directors of: Nanostring Technologies from May 2017 to June 2024; Laserscope from Augt 2005 until July 2006 when Laserscope was sold to American Medical Systems; Thoratec, a developer, manufacturer and marketer of proprietary medical devices for mechanical circulatory support from July 2007 to May 2013; Altera Corporation, a manufacturer of programmable logic devices from September 2011 until December 2015, when Altera was sold to Intel; Cutera, Inc. a global provider of laser and other energy based aesthetic systems, from November 2017 to May 2019; and iRobot Corporation, a robotics technology company, from January 2017 to November 2021. - Elisha W. Finney，自2017年11月起担任董事。她担任审计委员会主席。她拥有乔治亚大学风险管理和保险工商管理学士学位，金门大学工商管理硕士学位。Finney是NanoString Technologies，Inc.的董事和审计委员会主席，以及ICU Medical, Inc.和Viatris Inc.的董事，她是这两家公司的审计委员会成员。她此前曾担任Cutera，Inc.的董事至2019年6月，Irobot Corporation至2021年11月。Finney女士自1999年至2017年6月退休期间一直担任Varian医疗 Inc.的首席财务官。她于1988年加入Varian，在被任命为首席财务官之前曾担任过多种财务职务。
- Elisha W. Finney has been a director since January 2016, and serves as Chair of the Nominating and Governance Committee and is a member of the Audit Committee. Ms. Finney, now retired, was named Vice President, Finance and CFO of Varian Medical Systems in April 1999. In January 2005, she was promoted to Senior Vice President and given additional management responsibility for the Corporate Information Systems group. She was named Executive Vice President in February 2012. Varian Medical Systems is a leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy. Ms. Finney managed a worldwide staff of 400. Her management responsibilities included corporate accounting; corporate communications and investor relations; internal financial and compliance audit; risk management; tax and treasury, and corporate information systems. Ms. Finney joined Varian as risk manager in 1988 and has assumed a wide variety of finance functions over her last 29 years with the company. Prior to joining Varian, Ms. Finney was with the Fox Group in Foster City, CA, and Beatrice Foods, a major food processing company, in Chicago, IL. Ms. Finney has served on the boards of: Mettler Toledo, a multinational manufacturer of scales and analytical instruments, since November 2017; and Viatris, a global pharmaceutical and healthcare corporation, since December 2022. Ms. Finney previoly served on the boards of directors of: Nanostring Technologies from May 2017 to June 2024; Laserscope from Augt 2005 until July 2006 when Laserscope was sold to American Medical Systems; Thoratec, a developer, manufacturer and marketer of proprietary medical devices for mechanical circulatory support from July 2007 to May 2013; Altera Corporation, a manufacturer of programmable logic devices from September 2011 until December 2015, when Altera was sold to Intel; Cutera, Inc. a global provider of laser and other energy based aesthetic systems, from November 2017 to May 2019; and iRobot Corporation, a robotics technology company, from January 2017 to November 2021.
- Domitille Doat Le Bigot
-
Domitille Doat Le Bigot从2020年2月开始担任董事。她拥有ESSEC商学院和墨尔本商学院的工商管理硕士学位。 自2016年以来，她一直担任达能的首席数字官，并且是嘉士伯集团董事会成员。
Domitille Doat Le Bigot has been a director since February 2020. She serves as Chair of the Nominating & Corporate Governance Committee. She has a Master's in Biness Administration from the ESSEC Biness School and the Melbne Biness School. She is the Operating Partner in Technology, AI Acceleration and Data for the portfolio of Eurazeo LBO Strategies.From April 2024 until 2026, Ms. Doat Le Bigot served as Chief Digital and Information Officer and a member of the Partners Committee at Eurazeo. She joined Eurazeo in April 2021 as its Chief Digital Officer. She is currently a member of the Board of Directors and the Audit Committee at Gaztransport & Technigaz (GTT) and was a member of the board at Carlsberg Group until 2020.Prior to her joining Eurazeo, Ms. Doat Le Bigot served as Chief Digital Officer at Danone from 2016 to 2021, and from 2014 to 2016 she served as Deputy General Manager and Head of Technology and Data in Shanghai and Paris at Fred & Farid Group, an international independent digital agency. Prior to 2014 she served in creative management and digital production and design positions at Cisco and Ubisoft Entertainment. - Domitille Doat Le Bigot从2020年2月开始担任董事。她拥有ESSEC商学院和墨尔本商学院的工商管理硕士学位。 自2016年以来，她一直担任达能的首席数字官，并且是嘉士伯集团董事会成员。
- Domitille Doat Le Bigot has been a director since February 2020. She serves as Chair of the Nominating & Corporate Governance Committee. She has a Master's in Biness Administration from the ESSEC Biness School and the Melbne Biness School. She is the Operating Partner in Technology, AI Acceleration and Data for the portfolio of Eurazeo LBO Strategies.From April 2024 until 2026, Ms. Doat Le Bigot served as Chief Digital and Information Officer and a member of the Partners Committee at Eurazeo. She joined Eurazeo in April 2021 as its Chief Digital Officer. She is currently a member of the Board of Directors and the Audit Committee at Gaztransport & Technigaz (GTT) and was a member of the board at Carlsberg Group until 2020.Prior to her joining Eurazeo, Ms. Doat Le Bigot served as Chief Digital Officer at Danone from 2016 to 2021, and from 2014 to 2016 she served as Deputy General Manager and Head of Technology and Data in Shanghai and Paris at Fred & Farid Group, an international independent digital agency. Prior to 2014 she served in creative management and digital production and design positions at Cisco and Ubisoft Entertainment.
- Wolfgang Wienand
-
Wolfgang Wienand,Wienand博士是Siegfried Holding AG （SIX： SFZN）的首席执行官，Siegfried Holding AG是制药行业合同开发和制造（CDMO）的全球领导者。他于2010年加入Siegfried，担任执行委员会成员，最初担任首席科学官，然后担任首席战略官，后来在2019年成为首席执行官之前同时担任这两个职位。加入Siegfried之前，他曾担任Evonik Industries AG（全球领先的特种化学品公司）的高级管理职位。
Wolfgang Wienand has been a director since November 2023. He serves on the Compensation Committee. Since July 2024, he is the Chief Executive Officer of Lonza Group Ltd., the world's largest contract development and manufacturing organization (CDMO) for the pharmaceutical indtry. He studied chemistry at the University of Bonn and subsequently obtained a Ph.D. in organic and bioorganic chemistry from the University of Cologne. In addition, he holds an Executive Master's Degree in International Finance of cole des hautes études commerciales HEC Paris.From January 2019 until March 2024, Dr. Wienand served as CEO of Siegfried Holding AG, a globally leading CDMO for the pharmaceutical indtry. He joined Siegfried in 2010, initially as Chief Scientific Officer, then as Chief Strategy Officer, before becoming CEO. Prior to Siegfried, Dr. Wienand held senior management positions at Evonik Indtries AG, a leading global specialty chemicals company. Dr. Wienand served as a non executive board member for SCHOTT Pharma until December 2024. - Wolfgang Wienand,Wienand博士是Siegfried Holding AG （SIX： SFZN）的首席执行官，Siegfried Holding AG是制药行业合同开发和制造（CDMO）的全球领导者。他于2010年加入Siegfried，担任执行委员会成员，最初担任首席科学官，然后担任首席战略官，后来在2019年成为首席执行官之前同时担任这两个职位。加入Siegfried之前，他曾担任Evonik Industries AG（全球领先的特种化学品公司）的高级管理职位。
- Wolfgang Wienand has been a director since November 2023. He serves on the Compensation Committee. Since July 2024, he is the Chief Executive Officer of Lonza Group Ltd., the world's largest contract development and manufacturing organization (CDMO) for the pharmaceutical indtry. He studied chemistry at the University of Bonn and subsequently obtained a Ph.D. in organic and bioorganic chemistry from the University of Cologne. In addition, he holds an Executive Master's Degree in International Finance of cole des hautes études commerciales HEC Paris.From January 2019 until March 2024, Dr. Wienand served as CEO of Siegfried Holding AG, a globally leading CDMO for the pharmaceutical indtry. He joined Siegfried in 2010, initially as Chief Scientific Officer, then as Chief Strategy Officer, before becoming CEO. Prior to Siegfried, Dr. Wienand held senior management positions at Evonik Indtries AG, a leading global specialty chemicals company. Dr. Wienand served as a non executive board member for SCHOTT Pharma until December 2024.
- Pablo Perversi
-
Pablo Perversi自2025年11月起担任董事。自2026年5月7日起，他将加入审计委员会。他是全球领先的食品和饮料公司达能（Danone）的欧洲、中东和非洲地区总裁，也是其执行委员会成员。在担任现职之前，他曾于2023年至2025年担任达能欧洲区总裁，并于2017年至2022年担任百乐嘉利宝首席创新、质量和可持续性官以及GMET部门总裁。在此之前，他曾于1993年至2017年在联合利华担任过越来越多的职务，他在那里的最后一个职位是欧洲食品公司副总裁。
Pablo Perversi has been a director since November 2025. Effective May 7, 2026, he will join the Audit Committee. He is President of EMEA at Danone, a leading global food and beverage company, and a member of its Executive Committee. Prior to his current role, he served as Danone's Europe Zone President from 2023 to 2025, and the Chief Innovation, Quality, and Stainability Officer and President of Gmet Division for Barry Callebaut from 2017 to 2022. Before that, he held vario roles of increasing responsibility at Unilever from 1993 to 2017, his last position there being Vice President of Foods Europe. - Pablo Perversi自2025年11月起担任董事。自2026年5月7日起，他将加入审计委员会。他是全球领先的食品和饮料公司达能（Danone）的欧洲、中东和非洲地区总裁，也是其执行委员会成员。在担任现职之前，他曾于2023年至2025年担任达能欧洲区总裁，并于2017年至2022年担任百乐嘉利宝首席创新、质量和可持续性官以及GMET部门总裁。在此之前，他曾于1993年至2017年在联合利华担任过越来越多的职务，他在那里的最后一个职位是欧洲食品公司副总裁。
- Pablo Perversi has been a director since November 2025. Effective May 7, 2026, he will join the Audit Committee. He is President of EMEA at Danone, a leading global food and beverage company, and a member of its Executive Committee. Prior to his current role, he served as Danone's Europe Zone President from 2023 to 2025, and the Chief Innovation, Quality, and Stainability Officer and President of Gmet Division for Barry Callebaut from 2017 to 2022. Before that, he held vario roles of increasing responsibility at Unilever from 1993 to 2017, his last position there being Vice President of Foods Europe.
- Thomas P. Salice
-
Thomas P. Salice，2005年1月至今为私募股权公司 SFW Capital Partners, LLC 的联合创始人兼管理成员。曾在私募股权公司 AEA Investors, Inc. 担任各种职务，包括董事总经理、总裁兼首席执行官和副主席（1989年6月至2004年12月）。几家私营公司的董事：Filtec and Gerson Lehrman Group, Inc. 和 Micromeritics Instrument Corporation。
Thomas P. Salice has been a director since October 1996. He serves as Chair of the Compensation Committee and serves on the Nominating & Corporate Governance Committee. He has a Master's in Biness Administration from Harvard University. Mr. Salice is a co founder, principal, and Managing Member of SFW Capital Partners, LLC. Mr. Salice was a Director of Waters Corporation until July 2022, and he is currently a Director of the privately held companies Caron Products and Services Inc., Gerson Lehrman Group, Inc., Pion Inc., and RDI Technologies.Mr. Salice has been a Managing Member of SFW Capital Partners since January 2005. From June 1989 to December 2004, he served in a variety of capacities with AEA Investors, Inc., including Managing Director, President and Chief Executive Officer, and Vice Chair. - Thomas P. Salice，2005年1月至今为私募股权公司 SFW Capital Partners, LLC 的联合创始人兼管理成员。曾在私募股权公司 AEA Investors, Inc. 担任各种职务，包括董事总经理、总裁兼首席执行官和副主席（1989年6月至2004年12月）。几家私营公司的董事：Filtec and Gerson Lehrman Group, Inc. 和 Micromeritics Instrument Corporation。
- Thomas P. Salice has been a director since October 1996. He serves as Chair of the Compensation Committee and serves on the Nominating & Corporate Governance Committee. He has a Master's in Biness Administration from Harvard University. Mr. Salice is a co founder, principal, and Managing Member of SFW Capital Partners, LLC. Mr. Salice was a Director of Waters Corporation until July 2022, and he is currently a Director of the privately held companies Caron Products and Services Inc., Gerson Lehrman Group, Inc., Pion Inc., and RDI Technologies.Mr. Salice has been a Managing Member of SFW Capital Partners since January 2005. From June 1989 to December 2004, he served in a variety of capacities with AEA Investors, Inc., including Managing Director, President and Chief Executive Officer, and Vice Chair.
- Michael J. Tokich
-
Michael J. Tokich自2014年2月起担任高级副总裁、首席财务官兼财务主管。2008年3月至2014年2月他曾任高级副总裁兼首席财务官。
Michael J. Tokich has been a director since February 2026. He serves on the Audit Committee. Since Augt 2025, Mr. Tokich serves as the Senior Financial Advisor at STERIS plc, a leading global healthcare and life science provider of products and services. Prior to his current role, Mr. Tokich most recently served STERIS as Senior Vice President and Chief Financial Officer. Mr. Tokich joined STERIS in 2000 and held vario senior financial roles prior to his appointment as CFO in 2008. - Michael J. Tokich自2014年2月起担任高级副总裁、首席财务官兼财务主管。2008年3月至2014年2月他曾任高级副总裁兼首席财务官。
- Michael J. Tokich has been a director since February 2026. He serves on the Audit Committee. Since Augt 2025, Mr. Tokich serves as the Senior Financial Advisor at STERIS plc, a leading global healthcare and life science provider of products and services. Prior to his current role, Mr. Tokich most recently served STERIS as Senior Vice President and Chief Financial Officer. Mr. Tokich joined STERIS in 2000 and held vario senior financial roles prior to his appointment as CFO in 2008.
- Brian Shepherd
-
Brian Shepherd从2005年10月到2009年3月担任产品管理部的部门副总裁，从2005年5月到2005年9月，担任产品管理部的高级副总裁，从2004年10月到2005年5月，担任技术营销部的高级副总裁。Shepherd先生于1996年加入PTC。
Brian Shepherd has been a director since July 2024. He currently serves on the Audit Committee. Effective May 7, 2026, he will rotate off the Audit Committee and join the Compensation Committee. Mr. Shepherd most recently served as the Senior Vice President, Software and Control, of Rockll Automation, Inc. from February 2021 through June 2024. Prior to this role, he was Division President, Production Software and Smart Factory, for Hexagon from 2017 to 2020. Mr. Shepherd previoly held a variety of senior leadership roles at PTC Inc. over the cse of his tnty year tenure with the company, including as Executive Vice President and General Manager, Enterprise Segments, and Executive Vice President, Product Development. - Brian Shepherd从2005年10月到2009年3月担任产品管理部的部门副总裁，从2005年5月到2005年9月，担任产品管理部的高级副总裁，从2004年10月到2005年5月，担任技术营销部的高级副总裁。Shepherd先生于1996年加入PTC。
- Brian Shepherd has been a director since July 2024. He currently serves on the Audit Committee. Effective May 7, 2026, he will rotate off the Audit Committee and join the Compensation Committee. Mr. Shepherd most recently served as the Senior Vice President, Software and Control, of Rockll Automation, Inc. from February 2021 through June 2024. Prior to this role, he was Division President, Production Software and Smart Factory, for Hexagon from 2017 to 2020. Mr. Shepherd previoly held a variety of senior leadership roles at PTC Inc. over the cse of his tnty year tenure with the company, including as Executive Vice President and General Manager, Enterprise Segments, and Executive Vice President, Product Development.
- Roland Diggelmann
-
Roland Diggelmann，自2022年8月起担任董事。他在审计委员会和薪酬委员会任职。他最近于2019年至2022年担任Smith & Nephew Plc首席执行官。在此之前，他曾于2012年至2018年担任Roche Diagnostics首席执行官，并于2008年至2012年担任亚太区董事总经理。在其职业生涯早期，Diggelmann曾在Zimmer Holdings、Centerpulse和Sulzer Medica担任多个高级管理职位。他是Sonova Holding AG的董事和提名与薪酬委员会成员，并且是瑞士公民。
Roland Diggelmann has been a director since Augt 2022 and Board Chair since May 2024. He most recently served as the Chief Executive Officer of Smith & Nephew Plc from 2019 2022. Prior to this role, he was CEO of Roche Diagnostics from 2012 to 2018 and managing director of the Asia Pacific region from 2008 to 2012.Earlier in his career, Mr. Diggelmann served in vario senior management roles at Zimmer Holdings, Centerpulse, and Sulzer Medica. He is a Director and serves as Chair of the Nomination and Compensation Committee at Sonova Holding AG, and is a Swiss citizen. - Roland Diggelmann，自2022年8月起担任董事。他在审计委员会和薪酬委员会任职。他最近于2019年至2022年担任Smith & Nephew Plc首席执行官。在此之前，他曾于2012年至2018年担任Roche Diagnostics首席执行官，并于2008年至2012年担任亚太区董事总经理。在其职业生涯早期，Diggelmann曾在Zimmer Holdings、Centerpulse和Sulzer Medica担任多个高级管理职位。他是Sonova Holding AG的董事和提名与薪酬委员会成员，并且是瑞士公民。
- Roland Diggelmann has been a director since Augt 2022 and Board Chair since May 2024. He most recently served as the Chief Executive Officer of Smith & Nephew Plc from 2019 2022. Prior to this role, he was CEO of Roche Diagnostics from 2012 to 2018 and managing director of the Asia Pacific region from 2008 to 2012.Earlier in his career, Mr. Diggelmann served in vario senior management roles at Zimmer Holdings, Centerpulse, and Sulzer Medica. He is a Director and serves as Chair of the Nomination and Compensation Committee at Sonova Holding AG, and is a Swiss citizen.
- Ingrid Zhang
-
Ingrid Zhang，自2023年2月起担任董事。她目前是Novartis创新药物中国区总裁。在担任这一职务之前，她曾在2017年至2022年期间担任Novartis制药中国区总裁，自2011年以来，她还在Novartis担任过多个领导职务，职责越来越多。在加入Novartis之前，Zhang女士曾在AstraZeneca、Pfizer和McKinsey & Company担任过多个高级管理职位。
Ingrid Zhang has been a director since February 2023. She serves on the Nominating & Corporate Governance Committee. She is currently the Chief Commercial Officer, International, at Novartis. Prior to this role she was President and Managing Director of Novartis China from October 2023 to May 2024, President of China, Innovative Medicines at Novartis, from 2022 to October 2023, President Novartis Pharmaceuticals China from 2017 to 2022, and held several other leadership positions with increasing responsibilities at Novartis since 2011. Prior to Novartis, Ms. Zhang held vario senior management roles with AstraZeneca, Pfizer, and McKinsey & Company. - Ingrid Zhang，自2023年2月起担任董事。她目前是Novartis创新药物中国区总裁。在担任这一职务之前，她曾在2017年至2022年期间担任Novartis制药中国区总裁，自2011年以来，她还在Novartis担任过多个领导职务，职责越来越多。在加入Novartis之前，Zhang女士曾在AstraZeneca、Pfizer和McKinsey & Company担任过多个高级管理职位。
- Ingrid Zhang has been a director since February 2023. She serves on the Nominating & Corporate Governance Committee. She is currently the Chief Commercial Officer, International, at Novartis. Prior to this role she was President and Managing Director of Novartis China from October 2023 to May 2024, President of China, Innovative Medicines at Novartis, from 2022 to October 2023, President Novartis Pharmaceuticals China from 2017 to 2022, and held several other leadership positions with increasing responsibilities at Novartis since 2011. Prior to Novartis, Ms. Zhang held vario senior management roles with AstraZeneca, Pfizer, and McKinsey & Company.
高管简历
中英对照 | 中文 | 英文- Patrick Kaltenbach
Patrick Kaltenbach于2021年1月加入Mettler-Toledo International Inc.，担任候任首席执行官，自2021年4月1日起担任首席执行官。在加入公司之前，他自2018年起担任Becton Dickinson生命科学部门的总裁。2014年至2018年，他担任安捷伦生命科学和应用市场集团总裁。此前，自1991年加入安捷伦及其前身惠普（Hewlett-Packard）以来，他在安捷伦（Agilent）担任了范围广泛且越来越多的领导职务。
Patrick Kaltenbach joined the Company in January 2021 and assumed the role of Chief Executive Officer beginning April 1, 2021. Prior to joining the Company, he served as the President of the Life Sciences Segment at Becton Dickinson since 2018. Mr. Kaltenbach was President of Life Sciences and Applied Markets Group at Agilent from 2014 to 2018. He held wide ranging and increasing leadership roles at Agilent and its predecessor company, Hewlett Packard, since joining in 1991.- Patrick Kaltenbach于2021年1月加入Mettler-Toledo International Inc.，担任候任首席执行官，自2021年4月1日起担任首席执行官。在加入公司之前，他自2018年起担任Becton Dickinson生命科学部门的总裁。2014年至2018年，他担任安捷伦生命科学和应用市场集团总裁。此前，自1991年加入安捷伦及其前身惠普（Hewlett-Packard）以来，他在安捷伦（Agilent）担任了范围广泛且越来越多的领导职务。
- Patrick Kaltenbach joined the Company in January 2021 and assumed the role of Chief Executive Officer beginning April 1, 2021. Prior to joining the Company, he served as the President of the Life Sciences Segment at Becton Dickinson since 2018. Mr. Kaltenbach was President of Life Sciences and Applied Markets Group at Agilent from 2014 to 2018. He held wide ranging and increasing leadership roles at Agilent and its predecessor company, Hewlett Packard, since joining in 1991.
- Shawn P. Vadala
Shawn P. Vadala，他于1997年加入公司，并一直担任首席财务官（2004年1月以来）。他负责公司的定价和商业智能项目。他此前曾担任公司的俄亥俄州哥伦布、瑞士格里芬湖办公室的多种高级财务职务。加入公司之前，他曾任职PricewaterhouseCoopers公司的波士顿和瑞士、苏黎世办事处。
Shawn P. Vadala joined the Company in 1997 and has been Chief Financial Officer since January 2014 and also responsible for the Company's Pricing program since 2008. Mr. Vadala previoly held vario senior financial positions at the Company's Columb, Ohio and Greifensee, Switzerland offices and was also responsible for Biness Intelligence from 2010 to 2018. Prior to joining the Company, he worked in the Boston and Zurich, Switzerland offices of PricewaterhoeCoopers.- Shawn P. Vadala，他于1997年加入公司，并一直担任首席财务官（2004年1月以来）。他负责公司的定价和商业智能项目。他此前曾担任公司的俄亥俄州哥伦布、瑞士格里芬湖办公室的多种高级财务职务。加入公司之前，他曾任职PricewaterhouseCoopers公司的波士顿和瑞士、苏黎世办事处。
- Shawn P. Vadala joined the Company in 1997 and has been Chief Financial Officer since January 2014 and also responsible for the Company's Pricing program since 2008. Mr. Vadala previoly held vario senior financial positions at the Company's Columb, Ohio and Greifensee, Switzerland offices and was also responsible for Biness Intelligence from 2010 to 2018. Prior to joining the Company, he worked in the Boston and Zurich, Switzerland offices of PricewaterhoeCoopers.
- Gerhard Keller
Gerhard Keller，1991年加入公司，自2018年7月起担任过程分析主管，自2013年7月起担任移液器主管。他此前担任东亚/太平洋区域主管，还曾在欧洲和亚太地区担任多个销售和营销领导职能。在加入公司之前，他曾在瑞士的Sandoz（现为诺华）从事质量控制工作。
Gerhard Keller joined the Company in 1991 and has been Head of Process Analytics since July 2018 and Head of Pipettes since July 2013. He previoly was Head of Region East Asia/Pacific and also served in vario Sales and Marketing leadership functions in Europe and Asia Pacific. Prior to joining the Company, he worked in Quality Control at Sandoz, now Novartis, in Switzerland.- Gerhard Keller，1991年加入公司，自2018年7月起担任过程分析主管，自2013年7月起担任移液器主管。他此前担任东亚/太平洋区域主管，还曾在欧洲和亚太地区担任多个销售和营销领导职能。在加入公司之前，他曾在瑞士的Sandoz（现为诺华）从事质量控制工作。
- Gerhard Keller joined the Company in 1991 and has been Head of Process Analytics since July 2018 and Head of Pipettes since July 2013. He previoly was Head of Region East Asia/Pacific and also served in vario Sales and Marketing leadership functions in Europe and Asia Pacific. Prior to joining the Company, he worked in Quality Control at Sandoz, now Novartis, in Switzerland.
- Richard Wong
Richard Wong自2009年起担任亚太市场组织负责人。在2008年加入公司之前，他曾于1998年至2008年在安捷伦科技公司担任过多个区域管理职位，包括总部位于北京和东京的北亚生命科学现场运营。1991年，他在惠普公司开始了他的职业生涯，并在销售与市场营销和财务部门担任了越来越多的职务。
Richard Wong has been Head of Asia/Pacific since 2009. Prior to joining the Company in 2008, he held vario regional management positions with Agilent Technologies from 1998 to 2008 including Life Sciences Field Operations for North Asia based in Beijing and later in Tokyo. He started his career with Hewlett Packard in 1991 and held positions of increasing responsibilities in Sales and Marketing and Finance.- Richard Wong自2009年起担任亚太市场组织负责人。在2008年加入公司之前，他曾于1998年至2008年在安捷伦科技公司担任过多个区域管理职位，包括总部位于北京和东京的北亚生命科学现场运营。1991年，他在惠普公司开始了他的职业生涯，并在销售与市场营销和财务部门担任了越来越多的职务。
- Richard Wong has been Head of Asia/Pacific since 2009. Prior to joining the Company in 2008, he held vario regional management positions with Agilent Technologies from 1998 to 2008 including Life Sciences Field Operations for North Asia based in Beijing and later in Tokyo. He started his career with Hewlett Packard in 1991 and held positions of increasing responsibilities in Sales and Marketing and Finance.
- Susan Graham Bryce
San Graham Bryce于2025年加入公司，担任首席人力资源官。在加盟该公司之前，她曾在GE Healthcare担任首席人才官。格雷厄姆·布莱斯女士曾在通用电气担任多个行业和地区的各种全球人力资源领导职务，包括在德国、法国、英国、肯尼亚和美国的任务。
Susan Graham Bryce joined the company in 2025 as Chief Human Resces Officer. Prior to joining the company, she served as Chief Talent Officer at GE HealthCare. Ms. Graham Bryce has held a variety of global HR leadership roles at GE across multiple indtries and geographies, including assignments in Germany, France, the United Kingdom, Kenya, and the United States.- San Graham Bryce于2025年加入公司，担任首席人力资源官。在加盟该公司之前，她曾在GE Healthcare担任首席人才官。格雷厄姆·布莱斯女士曾在通用电气担任多个行业和地区的各种全球人力资源领导职务，包括在德国、法国、英国、肯尼亚和美国的任务。
- Susan Graham Bryce joined the company in 2025 as Chief Human Resces Officer. Prior to joining the company, she served as Chief Talent Officer at GE HealthCare. Ms. Graham Bryce has held a variety of global HR leadership roles at GE across multiple indtries and geographies, including assignments in Germany, France, the United Kingdom, Kenya, and the United States.
- Oliver Wittorf
Oliver Wittorf于2004年加入公司，曾在瑞士、美国和中国的运营、供应链管理和IT领域担任多个领导职务。他于2010年担任全球供应链管理主管，并于2020年额外负责零售部门和2026年产品检验部门，并于2017年至2025年还负责信息技术。在加入公司之前，Wittorf先生曾在瑞士的一家企业融资咨询公司工作。
Oliver Wittorf joined the Company in 2004 and held vario leadership positions in Operations, Supply Chain Management and IT in Switzerland, the , and China. He assumed the role of Head of Global Supply Chain Management in 2010 with additional responsibility for the Retail Division in 2020 and the Product Inspection Division in 2026, and was also responsible for Information Technology from 2017 to 2025. Prior to joining the Company, Mr. Wittorf worked for a corporate finance advisory firm in Switzerland.- Oliver Wittorf于2004年加入公司，曾在瑞士、美国和中国的运营、供应链管理和IT领域担任多个领导职务。他于2010年担任全球供应链管理主管，并于2020年额外负责零售部门和2026年产品检验部门，并于2017年至2025年还负责信息技术。在加入公司之前，Wittorf先生曾在瑞士的一家企业融资咨询公司工作。
- Oliver Wittorf joined the Company in 2004 and held vario leadership positions in Operations, Supply Chain Management and IT in Switzerland, the , and China. He assumed the role of Head of Global Supply Chain Management in 2010 with additional responsibility for the Retail Division in 2020 and the Product Inspection Division in 2026, and was also responsible for Information Technology from 2017 to 2025. Prior to joining the Company, Mr. Wittorf worked for a corporate finance advisory firm in Switzerland.